Khiron Life Sciences Corp. (“Khiron” or the”Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis pioneer with center operations in Latin America and Europe, announces it has entered into a private arrangement with Medline, a major marketer and distributor of pharmaceutical products to hospitals pharmacies and hospitals in southern Brazil. Through this agreement, doctors in Medlive’s extensive network is going to get medical instruction and training associated with Khiron products.”Brazil represents among the most important markets in Latin America, with its large population and its approval of medical cannabis.
Together with Medline, we’re now positioned to start teaching caregivers and forging prescriptions for our medical cannabis products and finally focus on our aim to assist patients from Brazil who will reap the benefits of medical cannabis,” opinions Alvaro Torres, Khiron CEO, and manager. “Medline is known as a significant medical advertising and marketing organization in the area, and we couldn’t have a better companion to help us reach these aims.”On November 29th, 2019 Khiron declared it had obtained consent in the Colombian Technical Quotas Group (“TQG”) for the commercialization of health usage high THC cannabis for domestic and export purposes, such as to Uruguay. On February 7th, 2020, the Company declared authorization in the Brazilian Health Regulatory Agency (ANVISA) to get Khiron medical cannabis merchandise to be imported to be used on a single patient basis.
The health cannabis market in Brazil is expected to rise to 3.4 million sufferers and a marketplace of US$1.4 Billion in just three decades, including helping patients with chronic pain conditions (Source: New Frontier Data 2017). Further, total asks for medical cannabis have skyrocketed because of 2015 (Source: ANVISA), and now, roughly 1,100 doctors are now prescribing medical cannabis for their patients.”With the rapid globalization of medical cannabis, such as here in Brazil, there’s an important requirement to deliver merchandise instruction and advice regarding the nation’s caregivers. When medical professionals consider medical cannabis here, they consider Khiron. Khiron was the ideal option to have a spouse, and also to deliver their highly recognized product research and development experience to our wellbeing,” opinions Adriana Marques, Medline Managing Director.About MedliveMedlive is a pioneer in the supply of health and hospital goods in the south of Brazil, serving over 3,000 hospitals and hospitals in the general public and private businesses. Medline delivers effective, powerful, and agile results via a broad portfolio of medications and nutritional products, as well as alternatives that are employed throughout the supply chain for ailments including cancer therapies and clinical nutrition, amongst others.Medline is a dedicated business partner, understanding demands and also with technical and scientific understanding in the fields of pharmacology, nursing, and nourishment that make the business a significant source in the supply of medication solutions.
The business can move at pace to encourage the health care community from the south and southeast areas, and with the ability for the whole Brazilian territory. Stop by http://medlive.com.brAround Khiron Life Sciences Corp.Khiron Life Sciences Corp. is the most dominant incorporated medical cannabis Business in Latin America. Khiron has center operations in Latin America, together with action in North America and Europe, and is licensed in Colombia for its cultivation, manufacturing, national supply, and global export of equally tetrahydrocannabinol (THC) and cannabidiol (CBD) clinical cannabis. The business delivers best in class regulatory compliance, has got the very first approved lineup of CBD cosmetic products on a shelf in Colombia, and is fully licensed to fabricate high- and – low-THC medical cannabis, also to fill prescriptions for low-THC medical cannabis from the nation.Using a concentrated regional approach and individual-oriented strategy, the business combines global scientific experience, agricultural benefits, branded merchandise market entry experience, and instruction to induce brand and prescription loyalty to deal with priority medical conditions like chronic pain, epilepsy, depression, and stress from the Latin American marketplace of over 620 million individuals. The business is directed by Co-founder and Chief Executive Officer, Alvaro Torres, as well as a seasoned executive team, and also an educated Board of Directors which includes former President of Mexico, Vicente Fox. This media release may contain certain”forward-looking information” and also”forward-looking statements” within the meaning of applicable securities laws.
All information contained herein that’s not historical can constitute back-end info. Khiron undertakes no duty to remark analyses, statements, or expectations made from third-parties regarding Khiron, its securities, or financial or operating results (as important ). Though Khiron believes that the expectations represented in forward-looking statements in this press release are reasonable, such forward-looking statement was predicated on expectations, assumptions and factors regarding future events that might prove to be erroneous and therefore are subject to numerous risks and uncertainties, certain of which are outside Khiron’s management, including the risk factors discussed in Khiron’s yearly Information Form that’s available on Khiron’s SEDAR profile in www.sedar.com. The forward-looking information included within this press release is expressly qualified by this cautionary statement and therefore are made as of this date hereof. This news release doesn’t constitute an offer to sell or a solicitation of an offer to purchase any of these securities from the USA. Neither the TSXV nor its Regulation Services Provider (as that phrase is described in the policies of this TSXV) take responsibility for the adequacy or accuracy of this press release.